Gregory v. Pronai Therapeutics Inc.
297 F. Supp. 3d 372
S.D. Ill.2018Background
- ProNAi was a clinical-stage biotech whose sole clinical drug candidate was PNT2258 (a DNAi-based therapy targeting BCL2). The IPO prospectus (July 15, 2015) and subsequent SEC filings repeatedly described preliminary Phase I/Phase II data and projected a registration-oriented development program while including extensive cautionary language about risks and uncertainty.
- Plaintiffs (a putative class of investors who bought ProNAi securities July 15, 2015–June 6, 2016) allege 70 false or misleading statements and omissions about PNT2258’s efficacy, protocol amendments, registration-readiness, and internal controls, asserting violations of §10(b), Rule 10b-5 and §20(a).
- Key factual allegations rested on internal preclinical and clinical developments: confidential witnesses claimed repeated negative preclinical findings; ProNAi amended Wolverine and Brighton trial protocols; several executives resigned during the Class Period; interim Wolverine/Brighton data ultimately prompted discontinuation of PNT2258 on June 6, 2016, causing a stock price collapse.
- Defendants moved to dismiss under Rules 12(b)(6) and 9(b)/PSLRA, arguing many challenged statements were non-actionable puffery, protected forward-looking statements, accompanied by meaningful cautionary language, or publicly disclosed (e.g., protocol amendments on ClinicalTrials.gov); they also disputed scienter and materiality.
- The Court found most challenged statements non-actionable (puffery, forward-looking with meaningful cautionary language, or already disclosed) but identified a narrow category of non-forward-looking opinion statements (post-September 2015) about PNT2258’s scientific potential that could be materially misleading for omitting persistently negative preclinical results communicated to executives.
- Even assuming some statements were materially misleading, the Court held plaintiffs failed to plead a strong inference of scienter (no concrete motive, no particularized facts showing conscious misbehavior or recklessness), and thus dismissed the Amended Complaint with prejudice.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Alleged misstatements re: Phase I/Pilot Phase II efficacy and safety | Statements overstated efficacy and omitted adverse events, discontinuations, and comparative disease-progression data | Phase I was a safety study; Pilot Phase II disclosures were qualified; many omissions were non-actionable (no duty) or immaterial | Dismissed: disclosures about Phase I/Pilot II not materially misleading as pled; omissions not shown to be material or to impose a duty to disclose |
| Non-disclosure of Wolverine/Brighton interim results and protocol amendments | Defendants should have disclosed adverse interim results and certain protocol amendments earlier because they made other efficacy statements | No duty to disclose interim results when company had not previously reported on those trials; many protocol amendments were publicly posted on ClinicalTrials.gov | Dismissed: no duty to update; protocol amendments were publicly disclosed; not actionable |
| Statements of scientific opinion and forward-looking commercialization claims (DNAi viability, market potential, registration strategy) | Opinions were misleading because defendants knew preclinical work uniformly showed DNAi/PNT2258 was ineffective; forward-looking statements were assurances without basis | Statements were forward-looking or opinion; accompanied by extensive, meaningful cautionary language (bespeaks-caution); opinions were sincerely held and not contradicted by disclosed facts | Narrow ruling: most forward-looking statements protected; but non-forward-looking opinion statements (post-Sept. 2015) could be misleading for omitting negative preclinical results — but scienter not pled sufficiently |
| Scienter and control-person liability under §20(a) | Executives had motive (raise IPO proceeds, acquire assets) and showed reckless conduct (resignations, withheld negative data) | Motive alleged is generic; resignations and internal disagreements do not establish fraud; plaintiffs fail to plead conscious misbehavior or strong circumstantial evidence of recklessness | Dismissed: plaintiffs failed to plead a strong inference of scienter; §20(a) claims dismissed because no primary violation adequately pled |
Key Cases Cited
- Bell Atl. Corp. v. Twombly, 550 U.S. 544 (pleading must be facially plausible)
- Ashcroft v. Iqbal, 556 U.S. 662 (legal conclusions not entitled to an assumption of truth)
- Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (holistic scienter inquiry; strong inference standard)
- Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27 (materiality and omissions analysis under Rule 10b-5)
- Basic Inc. v. Levinson, 485 U.S. 224 (no affirmative duty to disclose absent necessity to avoid misleading statements)
- TSC Indus., Inc. v. Northway, Inc., 426 U.S. 438 (materiality standard for securities disclosures)
- Novak v. Kasaks, 216 F.3d 300 (confidential witness pleading and access-to-information requirements)
- ATSI Communications, Inc. v. Shaar Fund, Ltd., 493 F.3d 87 (heightened pleading standards for securities fraud)
- Omnicare, Inc. v. Laborers District Council, 575 U.S. 175 (opinion statements actionable when omitted facts conflict with reasonable investor’s understanding)
- Slayton v. American Express Co., 604 F.3d 758 (PSLRA safe-harbor and meaningful cautionary language analysis)